Literature DB >> 25178983

Diagnostic and prognostic value of microRNA-21 in colorectal cancer: an original study and individual participant data meta-analysis.

Honghe Zhang1, Peiwei Li2, Haixing Ju3, Martin Pesta4, Vlastimil Kulda4, Wenjun Jin5, Mao Cai6, Changbao Liu6, Han Wu7, Jinming Xu8, Yao Ye8, Guanglin Zhang1, Enping Xu1, Jianting Cai9, Maode Lai1, Dajing Xia8, Jun Yang10, Yihua Wu11.   

Abstract

BACKGROUND: We aimed to systematically summarize the diagnostic and prognostic value of circulating/tissue miR21 in patients with colorectal cancer.
METHODS: An original study was conducted to explore the potential value of circulating miR21 in colorectal cancer diagnosis and tissue miR21 in colorectal cancer prognosis. PUBMED and EMBASE were searched (to August, 2013) to identify eligible studies. To explore the diagnostic performance of circulating miR21, meta-analysis methods were used to pool sensitivity, specificity, positive and negative likelihood ratio, diagnostic OR and to construct a summary ROC curve. For prognostic meta-analysis, study-specific HRs of tissue miR21 for survival were summarized. Subgroup and sensitivity analyses were applied to explore heterogeneity.
RESULTS: Finally, 14 studies (including our study) were included in the meta-analyses. The pooled sensitivity, specificity, and AUC of circulating miR21 were 0.76 [95% confidence interval (CI), 0.59-0.88], 0.81 (95% CI, 0.76-0.85), and 0.81 (95% CI, 0.78-0.85) in diagnosing colorectal cancer. Patients with higher expression of tissue miR21 had significant inferior overall survival (OS; pooled HR, 1.56; 95% CI, 1.16-2.11) and disease-free survival (DFS; pooled HR, 1.35; 95% CI, 1.08-1.69). The individual participant data (IPD) meta-analysis demonstrated that tissue miR21 level was independently associated with worse colorectal cancer OS (HR, 1.69; 95% CI, 1.07-2.67; P = 0.023), whereas this association seems to be confined to males (P = 0.007) but not for females (P = 0.845).
CONCLUSIONS: Circulating miR21 level has potential value for colorectal cancer early detection, whereas high tissue miR21 level is associated with adverse colorectal cancer prognosis. IMPACT: miR21 is a promising biomarker for early detection and prognosis of colorectal cancer. Cancer Epidemiol Biomarkers Prev; 23(12); 2783-92. ©2014 AACR. ©2014 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25178983     DOI: 10.1158/1055-9965.EPI-14-0598

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  15 in total

Review 1.  Epigenetics of colorectal cancer: emerging circulating diagnostic and prognostic biomarkers.

Authors:  Elisa Danese; Martina Montagnana
Journal:  Ann Transl Med       Date:  2017-07

2.  Circulating microRNA-21 as a potential diagnostic marker for colorectal cancer: A meta-analysis.

Authors:  Wei Yu; Zhanhuai Wang; L I Shen; Qichun Wei
Journal:  Mol Clin Oncol       Date:  2015-12-08

3.  Exosomal microRNA in plasma as a non-invasive biomarker for the recurrence of non-small cell lung cancer.

Authors:  Hitoshi Dejima; Hisae Iinuma; Rie Kanaoka; Noriyuki Matsutani; Masafumi Kawamura
Journal:  Oncol Lett       Date:  2017-01-04       Impact factor: 2.967

4.  Locked nucleic acid anti-miR-21 inhibits cell growth and invasive behaviors of a colorectal adenocarcinoma cell line: LNA-anti-miR as a novel approach.

Authors:  R Nedaeinia; M Sharifi; A Avan; M Kazemi; L Rafiee; M Ghayour-Mobarhan; R Salehi
Journal:  Cancer Gene Ther       Date:  2016-07-01       Impact factor: 5.987

Review 5.  Advances of exosome isolation techniques in lung cancer.

Authors:  Elham O Mahgoub; Ehsan Razmara; Amirreza Bitaraf; Fahimeh-Sadat Norouzi; Maryam Montazeri; Roudabeh Behzadi-Andouhjerdi; Mojtaba Falahati; Ke Cheng; Yousif Haik; Anwarul Hasan; Sadegh Babashah
Journal:  Mol Biol Rep       Date:  2020-08-12       Impact factor: 2.316

Review 6.  MicroRNAs as growth regulators, their function and biomarker status in colorectal cancer.

Authors:  Lina Cekaite; Peter W Eide; Guro E Lind; Rolf I Skotheim; Ragnhild A Lothe
Journal:  Oncotarget       Date:  2016-02-09

7.  Metformin-induced ablation of microRNA 21-5p releases Sestrin-1 and CAB39L antitumoral activities.

Authors:  Claudio Pulito; Federica Mori; Andrea Sacconi; Frauke Goeman; Maria Ferraiuolo; Patrizia Pasanisi; Carlo Campagnoli; Franco Berrino; Maurizio Fanciulli; Rebecca J Ford; Massimo Levrero; Natalia Pediconi; Ludovica Ciuffreda; Michele Milella; Gregory R Steinberg; Mario Cioce; Paola Muti; Sabrina Strano; Giovanni Blandino
Journal:  Cell Discov       Date:  2017-07-04       Impact factor: 10.849

Review 8.  The clinical role of microRNA-21 as a promising biomarker in the diagnosis and prognosis of colorectal cancer: a systematic review and meta-analysis.

Authors:  Qiliang Peng; Xueli Zhang; Ming Min; Li Zou; Peipei Shen; Yaqun Zhu
Journal:  Oncotarget       Date:  2017-07-04

Review 9.  Extracellular miRNA-21 as a novel biomarker in glioma: Evidence from meta-analysis, clinical validation and experimental investigations.

Authors:  Kai Qu; Ting Lin; Qing Pang; Tian Liu; Zhixin Wang; Minghui Tai; Fandi Meng; Jingyao Zhang; Yong Wan; Ping Mao; Xiaoqun Dong; Chang Liu; Wenquan Niu; Shunbin Dong
Journal:  Oncotarget       Date:  2016-06-07

10.  Serum microRNA signatures and metabolomics have high diagnostic value in colorectal cancer using two novel methods.

Authors:  Hai-Ning Liu; Tao-Tao Liu; Hao Wu; Yan-Jie Chen; Yu-Jen Tseng; Can Yao; Shu-Qiang Weng; Ling Dong; Xi-Zhong Shen
Journal:  Cancer Sci       Date:  2018-02-26       Impact factor: 6.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.